Vedanta Biosciences Says VE202 Phase 2 Study In Ulcerative Colitis Did Not Meet Primary Endpoint
Aug 13 (Reuters) - Vedanta Biosciences:
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.